It’s nice to have distractions from the difficulty of life with ALS, so I was in a pretty good mood for the past week because my brothers, sister-in-law, and nieces were visiting from out of town. But one afternoon, they all headed out to a retreat center about 45…
Finding Necessary Distractions From the Challenges of Life With ALS
Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy that is conditionally approved to treat amyotrophic lateral sclerosis (ALS) in South Korea. The trial, ALSummit (NCT04745299), is evaluating the safety of repeat NeuroNata-R injections and how well…
A U.S. Food and Drug Administration (FDA) advisory committee will meet Sept. 7 to discuss the approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals announced. While the application was granted priority review earlier this year, with a final decision expected by June…
This past week had me experiencing a roller coaster of emotions. I started with a feeling of pride while reading a recent study that validated my at-home voice therapy sessions. Next, curiosity drew me into investigating an innovative exercise program designed for Parkinson’s patients. Then, the week ended on a…
Using the approved treatment Radicava (edaravone) in a real-world setting resulted in a similar safety profile as that reported in clinical trials, with no new safety signals identified, according to a new report. The analysis involved more than 5,000 people with amyotrophic lateral sclerosis (ALS) who received the…
The U.S. Food and Drug Administration (FDA) has published on its website a five-year action plan meant to help advance the development of — and access to — treatments that may make life better and longer for people with amyotrophic lateral sclerosis (ALS) or other rare neurodegenerative diseases. The…
NeuroSense Therapeutics’ combination therapy PrimeC led to a significant decline in certain biomarkers of amyotrophic lateral sclerosis (ALS) when used as an add-on to standard of care treatment, a study found. Standard treatment alone, meanwhile, appeared to have no impact on these disease-related biomarkers. The preliminary results come from…
When my 12-year-old son, Isaac, went to mow the grass last week, he noticed that one of the tires had come off the rim. My husband, Todd, purchased the zero-turn lawn mower nine years ago, a few years after his ALS diagnosis, when his arms were too weak to…
Doing a muscle biopsy to look for abnormal clumps of the TDP-43 protein in the nerve fibers of muscle tissue may be useful for the early detection of amyotrophic lateral sclerosis (ALS), according to a single-center study from Japan. “It is difficult to diagnose ALS in its early stages…
Courtesy of Rick Jobus It is with deep sadness that we inform the ALS News Today community of the passing of our friend and treasured columnist, Rick Jobus, on June 19, 2022. Rick published the first installment of his column, “Notes From the ALS Front,”…
Recent Posts
- Mourning the loss of a leader, friend, and advocate for women with ALS
- Developer to test ALS therapy with help of Mass General’s MyMatch
- A story of a family’s loss offers guidance amid my grief with ALS
- MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS
- Holding the line: Why I’d keep my ALS progression exactly as it is